[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644957":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":30,"centralContacts":37,"locations":43,"responsibleParty":58,"collaborators":30,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":30,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":30,"enrollmentInfo":71,"targetDuration":30,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":30,"overallStatus":45,"whyStopped":30,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Cairo University","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Group A","EXPERIMENTAL","Patients will receive 5 ml of lidocaine 2% + 50 µg dexmedetomidine, with a total volume of 7 ml.",[13],"Drug: Lidocaine + Dexmedetomidine",{"label":15,"type":10,"description":16,"interventionNames":17},"Group B","Patients will receive 5 ml of lidocaine 2% + 100 mg magnesium sulphate 10%, with a total volume of 7 ml.",[18],"Drug: Lidocaine + Magnesium sulphate",{"label":20,"type":21,"description":22,"interventionNames":23},"Group C","ACTIVE_COMPARATOR","Patients will receive 7 ml of lidocaine 2% with no further additives.",[24],"Drug: Lidocaine",[26,31,34],{"type":27,"name":28,"description":11,"armGroupLabels":29,"otherNames":30},"DRUG","Lidocaine + Dexmedetomidine",[9],null,{"type":27,"name":32,"description":16,"armGroupLabels":33,"otherNames":30},"Lidocaine + Magnesium sulphate",[15],{"type":27,"name":35,"description":22,"armGroupLabels":36,"otherNames":30},"Lidocaine",[20],[38],{"name":39,"role":40,"phone":41,"phoneExt":30,"email":42},"Hebatullah S Abdelhamid, MD","CONTACT","00201044512277","drhebasalah593@gmail.com",[44],{"facility":5,"status":45,"city":46,"state":30,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"RECRUITING","Cairo","12613","Egypt","EG",{"type":51,"coordinates":52},"Point",[53,54],31.24967,30.06263,{"lat":54,"lon":53},[57],{"name":39,"role":40,"phone":41,"phoneExt":30,"email":42},{"type":59,"investigatorFullName":60,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"PRINCIPAL_INVESTIGATOR","Hebatallah Salah Abdelhamid","Lecturer of Anesthesia, Surgical Critical Care and Pain Management Department, Faculty of Medicine, Cairo University, Cairo, Egypt.","100644957","hemodynamic-effect-of-dexmedetomidine-versus-magnesium-sulphate-as-an-adjuvant-to-lidocaine-in-preemptive-peribulbar-block-in-patients-undergoing-dacryocystorhinostomy-under-general-anesthesia-100644957",false,"NCT07675616","Hemodynamic Effect of Dexmedetomidine Versus Magnesium Sulphate as an Adjuvant to Lidocaine in Preemptive Peribulbar Block in Patients Undergoing Dacryocystorhinostomy Under General Anesthesia","Hemodynamic Effect of Dexmedetomidine Versus Magnesium Sulphate as an Adjuvant to Lidocaine in Preemptive Peribulbar Block in Patients Undergoing Dacryocystorhinostomy Under General Anesthesia: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Both sexes.\n* American Society of Anesthesiologists (ASA) physical status I or II.\n* Undergoing elective Dacryocystorhinostomy (DCR) surgery under general anesthesia.\n\nExclusion Criteria:\n\n* Patients have local infection.\n* Allergic reaction or complications of the local anaesthesia (LA).\n* Coagulopathy defined as international normalized ratio (INR) \\> 1.5, platelet count \\\u003C 100,000\u002Fmm³, or ongoing anticoagulant therapy not adequately discontinued.\n* Uncontrolled systemic disease, defined as poorly controlled hypertension \\[systolic blood pressure (SBP) \\> 160 mmHg\\], uncontrolled diabetes mellitus (HbA1c \\> 8.5%), unstable ischemic heart disease, or decompensated hepatic or renal disease.\n* Uncooperative patients.","ALL","18 Years",{"count":72,"type":73},60,"ESTIMATED","INTERVENTIONAL",[76],"NA","This study aims to compare the hemodynamic effect of dexmedetomidine and magnesium sulphate as an adjuvant to lidocaine in preemptive peribulbar block in patients undergoing Dacryocystorhinostomy (DCR) under general anaesthesia (GA) .",[79,80,81,35,82,83,84],"Hemodynamic Effect","Dexmedetomidine","Magnesium Sulphate","Peribulbar Block","Dacryocystorhinostomy","General Anesthesia","2026-06-27",{"date":87,"type":88},"2026-06-30","ACTUAL",{"date":90,"type":88},"2026-05-16",{"date":92,"type":73},"2026-12-01",{"name":5,"class":6},1]